Final dosimetry results of IDEC-Y2B8 phase I II 90yttrium radioimmunothenapy trial in non-Hodgkin's lymphoma (NHL).

被引：0
|
作者：
Wiseman, GA
White, CA
Witzig, TA
Stabin, MG
Spies, S
Silverman, DH
Raubitschek, A
Gordon, L
Emmanouilides, C
Janakiraman, N
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Idec Pharmaceut Corp, San Diego, CA USA
[3] Northwestern Univ, Chicago, IL 60611 USA
[4] Univ Calif Los Angeles, Los Angeles, CA USA
[5] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[6] Henry Ford Hosp, Detroit, MI 48202 USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 1999年 / 40卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
260
引用
收藏
页码：64P / 64P
页数：1
相关论文
共 50 条
  • [11] Non-Hodgkin's lymphoma tumor and bone marrow radiation doses from radioimmunotherapy with IDEC-Y2B8 yttrium-90 anti-CD20 monoclonal antibody.
    Wiseman, GA
    Dunn, WL
    Witzig, TE
    White, CA
    Grillo-López, AJ
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (05) : 69P - 70P
  • [12] A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma
    Witzig, Thomas E.
    Wiseman, Gregory A.
    Maurer, Matthew J.
    Habermann, Thomas M.
    Micallef, Ivana N. M.
    Nowakowski, Grzegorz S.
    Ansell, Stephen M.
    Colgan, Joseph P.
    Inwards, David J.
    Porrata, Luis F.
    Link, Brian K.
    Zent, Clive S.
    Johnston, Patrick B.
    Shanafelt, Tait D.
    Allmer, Cristine
    Asmann, Yan W.
    Gupta, Mamta
    Ballas, Zuhair K.
    Smith, Brian J.
    Weiner, George J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (07) : 589 - 593
  • [13] Final results of a Phase I/II trial of fractionated radioimmunotherapy (RAIT) with anti-CD22 90Y-epratuzumab tetraxetan in relapsed/refractory non-Hodgkin lymphoma (NHL)
    Goldenberg, D. M.
    Kraeber-Bodere, F.
    Morschhauser, F.
    Petillon, M.
    Huglo, D.
    Meller, J.
    Kirsch, C.
    Kropp, J.
    Le Gouil, S.
    Le Gouil, S.
    Bodet-Milin, C.
    Teoh, N.
    Chatal, J.
    Wegener, W. A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S237 - S237
  • [14] Long-term follow-up of a phase I/II trial of radioimmunotherapy (RIT) with yttrium 90 (90Y) ibritumomab tiuxetan for CD20+B-cell non-Hodgkin's lymphoma (NHL).
    Gordon, LI
    Molina, A
    Emmanouilides, C
    Raubitschek, A
    Darif, M
    Schilder, RJ
    Wiseman, GA
    White, CA
    Witzig, TE
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 576S - 576S
  • [15] Phase I/II Trial of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
    Kallam, Avyakta
    Meza, Jane
    Bierman, Philip
    Lunning, Matthew A.
    Bociek, R. Gregory
    Armitage, James Olen
    Vose, Julie M.
    BLOOD, 2017, 130
  • [16] IDEC-Y2B8 (Y-90 conjugated anti-CD20) dosimetry calculated from In-111 anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkin's lymphoma (NHL) emphasis on bone marrow (BM).
    Wiseman, GA
    Solinger, AM
    GrilloLopez, A
    Stabin, M
    Dunn, WL
    Witzig, TE
    Spies, S
    Gordon, L
    Raubitschek, A
    Margolin, K
    Karvelis, K
    Janakiraman, N
    Silverman, DH
    Emmanoulides, C
    Royston, I
    Chinn, P
    Parker, E
    Carter, W
    White, CA
    BLOOD, 1997, 90 (10) : 2273 - 2273
  • [17] Dosimetry results of Oncolym™ in the treatment of refractory B-cell non-Hodgkin's lymphoma (NHL).
    Verkh, LI
    Murray, JL
    Kripas, CJ
    Wessels, BW
    Varma, VM
    Kahn, D
    Bushnell, DL
    Serafini, AN
    Oliver, JC
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1998, 13 (01) : 66 - 66
  • [18] Phase I trial of yttrium 90 ibritumomab tiuxetan (90Y-RIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL)
    Swinnen, L. J.
    Flinn, I. W.
    Kahl, B. S.
    Frey, E.
    Rogers, K.
    Jung, M.
    Jacene, H.
    Wahl, R. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [19] Localization of yttrium 90 ibritumomab tiuxetan (90Y IT) in patients with CD20+ non-Hodgkin's lymphoma (NHL).
    Jacobs, SA
    Swerdlow, SA
    Avril, N
    Vidnovic, N
    Foon, KA
    Harrison, AM
    McCarty, KS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 177S - 177S
  • [20] Phase I/II Study of Dasatinib In Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
    William, Basem M.
    Hohenstein, Maribeth
    Loberiza, Fausto R., Jr.
    Caponetti, Gabriel C.
    Bociek, R. Gregory
    Bierman, Philip
    Armitage, James O.
    Chan, Wing-Chung
    Vose, Julie M.
    BLOOD, 2010, 116 (21) : 131 - 131
12345